All In Biotech

Drug Trial Radar · NCT03465722

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 476 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

476

Actual

Start

Mar 26, 2018

Primary completion

Mar 9, 2020

Study completion Sep 15, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.

Conditions

  • GIST

Interventions

  • avapritinibDrug

    Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.

  • regorafenibDrug

    Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1Time frame: 24 Months

Locations

114 sites in 18 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Boulder, Colorado

  • Washington Hospital Center - Oncology and Hematology

    Washington D.C., District of Columbia

  • Mayo Clinic Cancer Center

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Northwestern Medicine

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • Washington University in Saint Louis

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • OHSU - Knight Cancer Institute

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • USO - Texas Oncology

    Dallas, Texas

  • Texas Oncology - Denton South

    Denton, Texas

  • University of Texas MD Anderson

    Houston, Texas

  • Texas Oncology - Waco

    Waco, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Summit Cancer Centers

    Spokane, Washington

  • Medical College of Wisconsin - Froedtert Hospital

    Milwaukee, Wisconsin

  • Flinders Medical Center

    Adelaide, Australia

  • Monash Health

    Clayton, Australia

  • The Canberra Hospital

    Garran, Australia

  • AKH, Klinik f. Innere Med. I, Onkologie

    Vienna, Austria

  • Institut Jules Bordet

    Brussels, Belgium

  • Leuven Cancer Institute

    Leuven, Belgium

  • Jewish General Hospital

    Montreal, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • University Health Network

    Toronto, Ontario, Canada

  • Beijing Cancer Hospital

    Beijing, China

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.